236 related articles for article (PubMed ID: 36943234)
21. Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.
Wentink M; Dalm V; Lankester AC; van Schouwenburg PA; Schölvinck L; Kalina T; Zachova R; Sediva A; Lambeck A; Pico-Knijnenburg I; van Dongen JJ; Pac M; Bernatowska E; van Hagen M; Driessen G; van der Burg M
Clin Immunol; 2017 Mar; 176():77-86. PubMed ID: 28104464
[TBL] [Abstract][Full Text] [Related]
22. Mutations in PIK3R1 can lead to APDS2, SHORT syndrome or a combination of the two.
Bravo García-Morato M; García-Miñaúr S; Molina Garicano J; Santos Simarro F; Del Pino Molina L; López-Granados E; Ferreira Cerdán A; Rodríguez Pena R
Clin Immunol; 2017 Jun; 179():77-80. PubMed ID: 28302518
[TBL] [Abstract][Full Text] [Related]
23. Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4
Bier J; Rao G; Payne K; Brigden H; French E; Pelham SJ; Lau A; Lenthall H; Edwards ESJ; Smart JM; Cole TS; Choo S; Joshi AY; Abraham RS; O'Sullivan M; Boztug K; Meyts I; Gray PE; Berglund LJ; Hsu P; Wong M; Holland SM; Notarangelo LD; Uzel G; Ma CS; Brink R; Tangye SG; Deenick EK
J Allergy Clin Immunol; 2019 Jul; 144(1):236-253. PubMed ID: 30738173
[TBL] [Abstract][Full Text] [Related]
24. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
[TBL] [Abstract][Full Text] [Related]
25. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
[TBL] [Abstract][Full Text] [Related]
27. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
[TBL] [Abstract][Full Text] [Related]
28. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
[TBL] [Abstract][Full Text] [Related]
29. APDS2 and SHORT Syndrome in a Teenager with PIK3R1 Pathogenic Variant.
Ramirez L; Tamayo W; Ale H
J Clin Immunol; 2020 Oct; 40(7):1020-1025. PubMed ID: 32778990
[TBL] [Abstract][Full Text] [Related]
30. A human immunodeficiency caused by mutations in the PIK3R1 gene.
Deau MC; Heurtier L; Frange P; Suarez F; Bole-Feysot C; Nitschke P; Cavazzana M; Picard C; Durandy A; Fischer A; Kracker S
J Clin Invest; 2014 Sep; 124(9):3923-8. PubMed ID: 25133428
[TBL] [Abstract][Full Text] [Related]
31. Systematic review of mortality and survival rates for APDS.
Hanson J; Bonnen PE
Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
[TBL] [Abstract][Full Text] [Related]
32. PI3Kδ and primary immunodeficiencies.
Lucas CL; Chandra A; Nejentsev S; Condliffe AM; Okkenhaug K
Nat Rev Immunol; 2016 Nov; 16(11):702-714. PubMed ID: 27616589
[TBL] [Abstract][Full Text] [Related]
33. Homeostatic and pathogenic roles of PI3Kδ in the human immune system.
Sogkas G; Adriawan IR; Dubrowinskaja N; Atschekzei F; Schmidt RE
Adv Immunol; 2020; 146():109-137. PubMed ID: 32327151
[TBL] [Abstract][Full Text] [Related]
34. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
35. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME; Wolkewitz M; Schwab C; Lorenzini T; Leiding JW; Aladjdi N; Abolhassani H; Abou-Chahla W; Aiuti A; Azarnoush S; Baris S; Barlogis V; Barzaghi F; Baumann U; Bloomfield M; Bohynikova N; Bodet D; Boutboul D; Bucciol G; Buckland MS; Burns SO; Cancrini C; Cathébras P; Cavazzana M; Cheminant M; Chinello M; Ciznar P; Coulter TI; D'Aveni M; Ekwall O; Eric Z; Eren E; Fasth A; Frange P; Fournier B; Garcia-Prat M; Gardembas M; Geier C; Ghosh S; Goda V; Hammarström L; Hauck F; Heeg M; Heropolitanska-Pliszka E; Hilfanova A; Jolles S; Karakoc-Aydiner E; Kindle GR; Kiykim A; Klemann C; Koletsi P; Koltan S; Kondratenko I; Körholz J; Krüger R; Jeziorski E; Levy R; Le Guenno G; Lefevre G; Lougaris V; Marzollo A; Mahlaoui N; Malphettes M; Meinhardt A; Merlin E; Meyts I; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neubert J; Neven B; Nieters A; Nove-Josserand R; Oksenhendler E; Ozen A; Olbrich P; Perlat A; Pac M; Schmid JP; Pacillo L; Parra-Martinez A; Paschenko O; Pellier I; Sefer AP; Plebani A; Plantaz D; Prader S; Raffray L; Ritterbusch H; Riviere JG; Rivalta B; Rusch S; Sakovich I; Savic S; Scheible R; Schleinitz N; Schuetz C; Schulz A; Sediva A; Semeraro M; Sharapova SO; Shcherbina A; Slatter MA; Sogkas G; Soler-Palacin P; Speckmann C; Stephan JL; Suarez F; Tommasini A; Trück J; Uhlmann A; van Aerde KJ; van Montfrans J; von Bernuth H; Warnatz K; Williams T; Worth AJJ; Ip W; Picard C; Catherinot E; Nademi Z; Grimbacher B; Forbes Satter LR; Kracker S; Chandra A; Condliffe AM; Ehl S;
J Allergy Clin Immunol; 2023 Oct; 152(4):984-996.e10. PubMed ID: 37390899
[TBL] [Abstract][Full Text] [Related]
36. Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort.
Oh J; Garabedian E; Fuleihan R; Cunningham-Rundles C
J Allergy Clin Immunol Pract; 2021 Nov; 9(11):4095-4102. PubMed ID: 34352450
[TBL] [Abstract][Full Text] [Related]
37. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
[TBL] [Abstract][Full Text] [Related]
38. Paradoxical dominant negative activity of an immunodeficiency-associated activating
Tomlinson PR; Knox R; Perisic O; Su HC; Brierley GV; Williams RL; Semple RK
bioRxiv; 2023 Dec; ():. PubMed ID: 38077044
[No Abstract] [Full Text] [Related]
39. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
40. Hyperactivated PI3Kδ promotes self and commensal reactivity at the expense of optimal humoral immunity.
Preite S; Cannons JL; Radtke AJ; Vujkovic-Cvijin I; Gomez-Rodriguez J; Volpi S; Huang B; Cheng J; Collins N; Reilley J; Handon R; Dobbs K; Huq L; Raman I; Zhu C; Li QZ; Li MO; Pittaluga S; Uzel G; Notarangelo LD; Belkaid Y; Germain RN; Schwartzberg PL
Nat Immunol; 2018 Sep; 19(9):986-1000. PubMed ID: 30127432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
